Trial Profile

A Phase I/II, Multicenter, Open-label, Clinical Trial of Intratumoral/Intralesional Administration of RGT100 in Subjects with Advanced or Recurrent Tumors.

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RGT 100 (Primary) ; RGT 100 (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man
Sponsors Merck Sharp & Dohme; Rigontec

Most Recent Events

22 May 2019 This trial has been completed in France, according to the European Clinical Trials Database record.
02 Feb 2019 This trial has been completed in United Kingdom, according to the European Clinical Trials Database record.
25 Oct 2018 According to a Merck media release, data from the study were presented at ESMO 2018.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com